Carmichael Hill & Associates’s Charles River Laboratories CRL Stock Holding History

Carmichael Hill & Associates’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.17K	Hold	11	–	–	﹤0.01%	706
2024 Q2	$2.27K	Sell	11 -3	-21%	-$680	﹤0.01%	694
2024 Q1	$3.79K	Sell	14 -5	-26%	-$1.19K	﹤0.01%	649
2023 Q4	$4.49K	Hold	19	–	–	﹤0.01%	654
2023 Q3	$3.72K	Hold	19	–	–	﹤0.01%	661
2023 Q2	$4K	Hold	19	–	–	﹤0.01%	654
2023 Q1	$3.83K	Hold	19	–	–	﹤0.01%	655
2022 Q4	$4.14K	Hold	19	–	–	﹤0.01%	639
2022 Q3	$4K	Hold	19	–	–	﹤0.01%	685
2022 Q2	$4K	Buy	19 +3	+19%	+$733	﹤0.01%	674
2022 Q1	$5K	Hold	16	–	–	﹤0.01%	681
2021 Q4	$6K	Hold	16	–	–	﹤0.01%	682
2021 Q3	$7K	Hold	16	–	–	﹤0.01%	644
2021 Q2	$6K	Sell	16 -1	-6%	-$334	﹤0.01%	651
2021 Q1	$5K	Hold	17	–	–	﹤0.01%	649
2020 Q4	$4K	Hold	17	–	–	﹤0.01%	647
2020 Q3	$4K	Hold	17	–	–	﹤0.01%	604
2020 Q2	$3K	Hold	17	–	–	﹤0.01%	594
2020 Q1	$2K	Hold	17	–	–	﹤0.01%	603
2019 Q4	$3K	Buy	+17	New	+$2.35K	﹤0.01%	598

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Carmichael Hill & Associates's CRL Position: Q3 2024 in Review

Carmichael Hill & Associates held its Charles River Laboratories (CRL) position steady in Q3 2024 at 11 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Carmichael Hill & Associates first reported a position in CRL in Q4 2019 and has held it in 20 quarters since. The position peaked at $7K in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

Carmichael Hill & Associates held 11 shares of Charles River Laboratories worth $2.17K as of Q3 2024.
Carmichael Hill & Associates left its Charles River Laboratories share count unchanged in Q3 2024.
Charles River Laboratories made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #706 holding.
Carmichael Hill & Associates first reported a position in Charles River Laboratories in Q4 2019 and has held it in 20 quarters since.
Carmichael Hill & Associates's Charles River Laboratories position peaked at $7K in Q3 2021.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.